Axsome Therapeutics Future Growth
Future criteria checks 6/6
Axsome Therapeutics is forecast to grow earnings and revenue by 65.1% and 37.2% per annum respectively. EPS is expected to grow by 65.3% per annum. Return on equity is forecast to be 63.6% in 3 years.
Key information
65.1%
Earnings growth rate
65.3%
EPS growth rate
Pharmaceuticals earnings growth | 23.5% |
Revenue growth rate | 37.2% |
Future return on equity | 63.6% |
Analyst coverage | Good |
Last updated | 18 May 2024 |
Recent future growth updates
Recent updates
Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
May 10Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Apr 13Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Mar 17Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges
Feb 21Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce
Dec 27Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Dec 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Sep 12Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Aug 08Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts
May 13Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 03Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?
Mar 01Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?
Nov 14Axsome Therapeutics: Clear Path Ahead For AXS07
Oct 05Axsome to resubmit marketing application for migraine therapy in Q3 2023
Sep 29Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity
Sep 16Axsome begins enrolling in late-stage study of migraine drug AXS-07
Sep 01Axsome gains 19% as FDA approves depression therapy
Aug 19Axsome Therapeutics Q2 2022 Earnings Preview
Aug 08Axsome: Breaking Bearish Trend
Jul 26Axsome: One Step At A Time
Jul 01Axsome And AXS-05: A Special Situation
May 02Axsome: A Growth Transition
Apr 13Axsome: A Speculative Buy, Undervalued Biotech With A Short-Term Catalyst
Apr 03Axsome: A Biotech With Potential Approval Of Several Drugs In Coming Years
Mar 19Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,117 | 291 | 191 | 223 | 12 |
12/31/2025 | 671 | -23 | -45 | -16 | 16 |
12/31/2024 | 376 | -233 | -191 | -131 | 16 |
3/31/2024 | 251 | -296 | -193 | -193 | N/A |
12/31/2023 | 271 | -239 | -146 | -145 | N/A |
9/30/2023 | 223 | -202 | -143 | -142 | N/A |
6/30/2023 | 182 | -184 | -112 | -111 | N/A |
3/31/2023 | 145 | -159 | -90 | -90 | N/A |
12/31/2022 | 50 | -187 | -117 | -117 | N/A |
9/30/2022 | 26 | -160 | -118 | -118 | N/A |
6/30/2022 | 9 | -150 | -123 | -122 | N/A |
3/31/2022 | N/A | -141 | -114 | -114 | N/A |
12/31/2021 | N/A | -130 | -109 | -108 | N/A |
9/30/2021 | N/A | -126 | -100 | -100 | N/A |
6/30/2021 | N/A | -114 | -89 | -89 | N/A |
3/31/2021 | N/A | -100 | -82 | -82 | N/A |
12/31/2020 | N/A | -103 | -79 | -78 | N/A |
9/30/2020 | N/A | -99 | -75 | -75 | N/A |
6/30/2020 | N/A | -95 | -70 | -70 | N/A |
3/31/2020 | N/A | -90 | -60 | -60 | N/A |
12/31/2019 | N/A | -68 | -46 | -46 | N/A |
9/30/2019 | N/A | -53 | -39 | -39 | N/A |
6/30/2019 | N/A | -42 | -34 | -34 | N/A |
3/31/2019 | N/A | -37 | -33 | -33 | N/A |
12/31/2018 | N/A | -31 | -30 | -30 | N/A |
9/30/2018 | N/A | -29 | -27 | -27 | N/A |
6/30/2018 | N/A | -27 | -27 | -27 | N/A |
3/31/2018 | N/A | -26 | -27 | -27 | N/A |
12/31/2017 | N/A | -29 | N/A | -26 | N/A |
9/30/2017 | N/A | -29 | N/A | -27 | N/A |
6/30/2017 | N/A | -30 | N/A | -26 | N/A |
3/31/2017 | N/A | -29 | N/A | -24 | N/A |
12/31/2016 | N/A | -27 | N/A | -21 | N/A |
9/30/2016 | N/A | -23 | N/A | -16 | N/A |
6/30/2016 | N/A | -21 | N/A | -13 | N/A |
3/31/2016 | N/A | -16 | N/A | -10 | N/A |
12/31/2015 | N/A | -12 | N/A | -7 | N/A |
9/30/2015 | N/A | -10 | N/A | -7 | N/A |
6/30/2015 | N/A | -6 | N/A | -6 | N/A |
3/31/2015 | N/A | -6 | N/A | -5 | N/A |
12/31/2014 | N/A | -6 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AXSM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Earnings vs Market: AXSM is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AXSM is expected to become profitable in the next 3 years.
Revenue vs Market: AXSM's revenue (37.2% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: AXSM's revenue (37.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AXSM's Return on Equity is forecast to be very high in 3 years time (63.6%).